- Synthetic biology
- Metabolic engineering
- Bio-based molecules
- Sustainable development
As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.Discover >
Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.Discover >
Abolis develops custom-order microorganisms able to produce molecules of interest via fermentation for the health, nutrition, chemistry and cosmetics sectors.
Abolis fuses recent advances in biology, bioinformatics, genetics and robotics to reprogram microorganisms for the production of molecules or proteins of interest. By modifying the metabolic pathways of life, the company’s technology creates industrial microbial strains capable of producing molecules of interest via fermentation.
The core concept guiding Abolis is to seek inspiration in and improve upon what nature has been doing for eons: biosynthesis.
DESCRIPTION OF THE PRODUCTS / SERVICES /TECHNOLOGY
With its synthetic biology platform, Abolis reliably provides businesses with the existing or novel molecules they need while maintaining sustainability (bio-based and/or biodegradable materials) and significantly reducing the environmental impact of molecular production.
Abolis accompanies its clients from the project study phase, through the securing of intellectual property and on to industrialization start-up
ACCOMPLISHMENTS / COLLABORATIONS / HIGHLIGHTS
Abolis works with a number of major groups in the cosmetics, pharmaceuticals and nutrition sectors.
The company was selected within the France Relance 2021 project.
As of year-end 2021, Abolis employs more than 40 people.
The first applications resulting from Abolis’ technology will reach the market in 2024.
Abolis pursues its own research program.
In parallel, the company establishes industrial partnerships to:
In same field
Activity of research, sale, production, distribution and marketing of all unregulated food and agri-food products.Discover
Standing Ovation is developing the production of casein via precision fermentation to enable non-animal-derived cheese and milk substitutes.Discover
STH BIOTECH is developing an innovative cannabis-based process for the reliable and sustainable production of active compounds for the well-being and healthcare sectors.Discover
Synovance has developed a revolutionary synthetic genomics platform for the conception of robust industrial bioproduction strains.Discover
We develop an in vitro manufactured targeted DNA vector to improve the efficiency of therapeutic cell transfection and to reduce the cost of gene-based therapies.Discover
Production as a service (PaaS) platform capable of producing recombinant proteins & enzymes cheaper and on a scale.Discover
Altar is a specialist in the conception and operation of automated fluidic continuous culture systems for adaptive laboratory evolution and the development of microbial strains for industry.Discover
YposKesi is the first French company to develop and manufacture gene and cell therapy products for rare diseases.Discover
WatchFrog markets in vivo biotechnological solutions for environmental risk assessment and the evaluation of the therapeutic, toxic or pollutant potential of all types of chemical, cosmetic or pharmaceutical compounds.Discover
R & D services in the field of transient expression of recombinant proteins in plants.Discover
Pharming specializes in the production of recombinant proteins in transgenic rabbit milk.Discover
Glowee is a cleantech startup developing a disruptive lighting technology based on bioluminescence (the natural light-producing property of certain living organisms).Discover
Global Bioenergies is developing a process to convert renewable resources into hydrocarbons through fermentation.Discover